NL-OMON37049撤回2 期
Single dose open-label PK/PD, safety and tolerability of dabigatran etexilate mesilate given at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 years and 1 year to less than 2 years. - 1160.89
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 11（—）
入选标准
- •Stable pediatric patients objectively diagnosed with a venous thrombotic event
排除标准
- •- weight less than 9 kg;
- •- previous history of cerebral venous thromboembolism;
- •- conditions associated with a increased risk of bleeding;
- •- severe renal dysfunction;
- •- active infective endocarditis;
- •- hepatic disease.
研究者
相似试验
进行中（未招募）
不适用
Single dose safety and tolerability of dabigatran etexilate solution in children 1 to < 12 years of ageEUCTR2009-013618-29-BESCS Boehringer Ingelheim Comm.V16
进行中（未招募）
不适用
Safety and tolerability of dabigatran etexilate solution in children 1 to < 12 years of ageEUCTR2009-013618-29-ATBoehringer Ingelheim RCV GmbH & Co KG16
进行中（未招募）
不适用
Safety and tolerability of dabigatran etexilate solution in children 1 to < 12 years of ageEUCTR2009-013618-29-LTBoehringer Ingelheim RCV GmbH & Co KG16
进行中（未招募）
1 期
Safety and tolerability of dabigatran etexilate solution in children 1 to < 12 years of ageEUCTR2009-013618-29-Outside-EU/EEABoehringer Ingelheim (Canada) Ltd/Ltée16
进行中（未招募）
不适用
Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia (PKiDs)Sleep Initiation and Maintenance DisordersMedDRA version: 17.1Level: PTClassification code 10040984Term: Sleep disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2014-004644-35-Outside-EU/EEASanofi-aventis42